Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06523868 · ClinicalTrials.gov registry record · NA
Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study
A NA study of Cancer Diagnosis, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 1,500
- Enrollment target
- 1
- Study location
NCT06523868 is a NA study of Cancer Diagnosis that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 1,500 participants, below the 6,544-participant average among 4 other Cancer Diagnosis trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06523868, a NA study of Cancer Diagnosis, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty. The name of the screening blood test being studied is: -GRAIL Galleri MCED test
Conditions Studied
Interventions
- OTHER GRAIL Galleri
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2028-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06523868
The ClinicalTrials.gov registry entry for NCT06523868 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,544-participant average among 4 other Cancer Diagnosis trials with a reported enrollment target (77% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer Diagnosis appearing as the primary indexed condition, and to 1 intervention - of which GRAIL Galleri is the first listed.
NCT06523868 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06523868 about?
NCT06523868 is a clinical study titled "Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study". The purpose of this research study is to evaluate the possible benefits of an investigational, but commercially available Galleri multi-cancer early detection (MCED) blood test which is designed to detect many types of cancer early in veterans who have served in the military in active duty. The nam...
What is the current status of trial NCT06523868?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,500 participants. The study started on 2025-03-31. Estimated completion is 2028-09-30.
What conditions does trial NCT06523868 study?
This clinical trial studies the following conditions: Cancer Diagnosis.
What interventions are being tested in trial NCT06523868?
The interventions under investigation include: GRAIL Galleri (OTHER).
Who is sponsoring clinical trial NCT06523868?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06523868 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer Diagnosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRISM for Depression and Anxiety in Young Adults With Cancer
ACTIVE NOT RECRUITING · NA
-
Building Resiliency Among Caregivers of Curvivors and Metavivors
COMPLETED · NA
-
Avera Cancer Sequencing and Analytics Protocol (ASAP)
RECRUITING
-
Clinical Validation of Immunovia Next-Generation Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.